MAGE: A Potential Drug Target for Cancer (P45428)

Target Name: Melanoma-Associated Antigen

NCBI ID: P45428

Melanoma-Associated Antigen

Other Name(s): MAGE

MAGE: A Potential Drug Target for Cancer

Melanoma-Associated Antigen (MAGE), also known as nonspecified subtype (MASE), is a protein that is expressed in various tissues and organs, including the skin, hair, nails, and mucous membranes. It is a member of the tumor antigen (TA) family, which includes proteins that are expressed in a variety of malignancies, including melanoma, skin cancer, and leukemia. MAGE is a potential drug target or biomarker in these diseases due to its potential role in the development and progression of these cancers.

MAGE is a 20-kDa protein that is expressed in various tissues and organs, including the skin, hair, nails, and mucous membranes. It is characterized by a N-terminus that consists of a 尾-sheet and a C-terminus that consists of a 纬-chain. The 尾-sheet is composed of alternating 尾-strands that are responsible for the protein's stability and structure. The 纬-chain is a long tail that is involved in MAGE's cell surface localization and interactions with other proteins.

MAGE is involved in a variety of cellular processes, including cell signaling, cell adhesion, and cell survival. It is a negative regulator of the cell cycle, which means that it promotes the growth and division of cells. MAGE has been shown to play a role in the regulation of cell cycle progression, apoptosis, and autophagy.

MAGE has also been shown to be involved in cancer progression. For example, MAGE has been shown to be overexpressed in various types of cancer, including melanoma, skin cancer, and breast cancer. It has also been shown to be associated with cancer stem cells, which are cells that have the ability to maintain the properties of cancer cells and contribute to their maintenance and proliferation.

MAGE is also a potential biomarker for cancer diagnosis and treatment. For example, MAGE has been used as a marker for the diagnosis of melanoma, which is a type of skin cancer that is highly aggressive and has a poor prognosis. Studies have shown that higher levels of MAGE are associated with the development and progression of melanoma.

In addition to its potential clinical applications, MAGE is also a potential drug target. For example, MAGE has been shown to interact with the drug PD-1, which is a checkpoint inhibitor that is used to treat various types of cancer. Studies have shown that MAGE can interact with PD-1 and can inhibit its effects. This suggests that MAGE may be a useful target for cancer treatment.

In conclusion, MAGE is a protein that is expressed in various tissues and organs and is involved in a variety of cellular processes, including cell signaling, cell adhesion, and cell survival. It is also involved in cancer progression and has been shown to be associated with cancer stem cells. In addition to its potential clinical applications, MAGE is also a potential drug target and may be a useful target for cancer treatment. Further research is needed to fully understand the role of MAGE in cancer biology and its potential as a drug.

Protein Name: Melanoma-Associated Antigen (nonspecified Subtype)

The "Melanoma-Associated Antigen Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Melanoma-Associated Antigen comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets